The Phase 3 ALLOHA-2 pause and pivot to preclinical in vivo programs push any potential revenue-generating milestones years out, while cash runway only extends to Q4 2027. Monitor for partnership announcements on the heme and autoimmunity programs, which could provide non-dilutive capital, and for IND filings for the solid tumor candidates in Q3 2027.
Drugs in focus
TCRX drug pipeline →TSC-101
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (paused)
- Time to market
- Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
- Next catalyst
- None dated
What to watchTSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $0.1680entry
- T+1 · 4d ago −4.40%α −4.04% · $0.1606
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
The company paused enrollment in its Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital and announced a strategic reorganization to focus on in vivo-engineered TCR-T therapies for solid tumors, with cash runway extending into Q4 2027.
Key Financial Metrics
Key Facts
- Revenue for Q3 2026 was $0.6 million, down 76% from $2.5 million in Q3 2025.
- Cash and cash equivalents were $73.0 million as of September 30, 2026, funding operations into Q4 2027.
- The company paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital.
- TScan announced a strategic reorganization to prioritize its in vivo solid tumor program, with two candidates in IND-enabling studies.
- The Amgen collaboration agreement was terminated in August 2026, impacting revenue.
- Stockholders' equity declined from $123.1 million at year-end 2025 to $38.0 million at September 30, 2026.
Financial Impact
Q3 2026 revenue $0.6M (down 76% YoY), net loss $33.1M, EPS -$0.25 vs consensus -$0.18; cash burn rate ~$27M per quarter; market cap $12M
Risk Factors
- Insufficient capital to complete the Phase 3 ALLOHA-2 trial; strategic partnerships may not materialize.
- Revenue decline due to termination of Amgen collaboration; no new revenue sources visible.
- Preclinical in vivo TCR-T program is early-stage with no IND filed; clinical and regulatory risks are high.
- Cash burn rate of ~$27M per quarter implies less than 3 years of runway; further dilution likely.
- Stockholders' equity has dropped sharply from $123M to $38M, indicating significant accumulated losses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-456865 |
| Document: tcrx-20261112.htm | 0001193125-26-456865 |
| Document: 0001193125-26-456865-index-headers.html | 0001193125-26-456865 |
| Document: 0001193125-26-456865-index.html | 0001193125-26-456865 |
| Document: 0001193125-26-456865.txt | 0001193125-26-456865 |
| 8-K Data (Synthetic) | 0001193125-26-456865 |
Track record
15 reports on TCRX
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Viewing Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers